Public funding for transformative drugs: the case of sofosbuvir

•Transformative drugs often emerge from investment by public and private actors.•Sofosbuvir changed hepatitis C care, but had public support through NIH.•An estimated $60.9 million in public dollars supported sofosbuvir’s development.•Government investment in drug development should be reflected in price and access.